IRIS-Onyx Cohort in the IRIS-DES Registry
Launched by SEUNG-JUNG PARK · Oct 30, 2015
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The IRIS-Onyx study is looking at how well a specific heart stent called the Onyx stent works compared to other similar stents that release medication to help keep arteries open. This is important for patients with conditions like coronary artery disease, where blood vessels can become blocked. The study is currently recruiting participants who are 19 years or older and are willing to provide written consent to take part in the research.
If you join this trial, you will receive the Onyx stent as part of your treatment. However, you cannot participate if you are receiving another heart stent at the same time, have severe heart issues, or are expected to live for less than a year. This study aims to understand not only how effective the Onyx stent is but also its safety for patients, helping doctors make better treatment choices in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 19 and more
- • Intervention with Onyx Drug Eluting Stent
- • Agreed with written informed consent form
- Exclusion Criteria:
- • Intervention with Onyx drug eluting coronary stent and other drug eluting stent at the same time
- • Life expectancy of 1year and under
- • Cardiac shock
About Seung Jung Park
Seung-Jung Park is a distinguished clinical trial sponsor recognized for his commitment to advancing medical research and innovation. With a focus on cardiology and interventional procedures, he leads initiatives that aim to improve patient outcomes through rigorous clinical trials. His expertise in trial design and execution ensures adherence to the highest ethical standards and regulatory requirements. By fostering collaboration among multidisciplinary teams, Seung-Jung Park drives the development of cutting-edge therapies, contributing significantly to the scientific community and enhancing the landscape of modern medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Incheon, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Ulsan, , Korea, Republic Of
Seoul, , Korea, Republic Of
Pusan, , Korea, Republic Of
Daegu, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, Songpa Gu, Korea, Republic Of
Kwangju, , Korea, Republic Of
Seoul, , Korea, Republic Of
Pusan, , Korea, Republic Of
Seoul, , Korea, Republic Of
Gangneung, , Korea, Republic Of
Cheonan, , Korea, Republic Of
Ilsan, , Korea, Republic Of
Jeonju, , Korea, Republic Of
Anyang, , Korea, Republic Of
Seoul, , Korea, Republic Of
Chuncheon, , Korea, Republic Of
Incheon, , Korea, Republic Of
Suncheon, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Yangsan, , Korea, Republic Of
Bucheon, , Korea, Republic Of
Seongnam, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Pusan, , Korea, Republic Of
Seoul, , Korea, Republic Of
Wonju, , Korea, Republic Of
Daejeon, Chungcheongnam Do, Korea, Republic Of
Gwangju, Jeollanam Do, Korea, Republic Of
Seoul, Republic Of Korea, Korea, Republic Of
Sungnam, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials